A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection

Trial Profile

A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Amoxicillin/omeprazole/rifabutin (Primary) ; Riboflavin
  • Indications Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ERADICATE Hp 2
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 15 Jun 2017 Status changed from not yet recruiting to recruiting, according to a RedHill Biopharma media release.
    • 10 Jan 2017 According to a RedHill Biopharma media release, this trial is planned to be initiated by April of 2017, after completion of the ongoing supportive PK program (see profile 280726 and 280729) and submission of clinical study reports to the FDA.
    • 14 Nov 2016 According to a RedHill Biopharma media release, this trial is expected to initiate in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top